A Phase 2/3 interventional study of G-SCF in Granulocyte Colony-stimulating Factor, Minimal Residual Disease and Acute Myeloid Leukemia, sponsored by Nanfang Hospital, Southern Medical University. Completed at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Nanfang Hospital, Southern Medical University · Phase 2/3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Neoplasm, Residual with a site in China — 52 open to participants now, 56 under way, 3 of them phase 3. Neoplasm, Residual · China.
Among the 78 studies in Neoplasm, Residual with a site in China, this one is the 2nd largest by enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 2/3, and was the 8th registered.
294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
Browse Neoplasm, Residual studies →52 of the 78 studies in Neoplasm, Residual with a site in China are open now. Recruiting first, the newest first:
Guangzhou University of Traditional Chinese Medicine · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18–75
Peking University People's Hospital · Sites in China
Ages 18–85
Rong Tao · Sites in China
Ages 18–80
Peking University People's Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 93 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 18 take children under 18; 7 take healthy volunteers.
This study: 14 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 28 · Phase 3 9
First in 2013; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 762 is above the median of 50 across 199 interventional studies indexed under Neoplasm, Residual.
Median enrollment 70 across the 48 interventional studies, 100 across the 30 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 78 have an industry lead sponsor. The 10 most frequent:
Nanfang Hospital, Southern Medical University is the lead sponsor of 490 studies on the registry; 213 are open to participants now.
Nanfang Hospital, Southern Medical University has 7 studies filed under Neoplasm, Residual — fewer than ten, so there is no comparison to draw.
15 of the studies in Neoplasm, Residual with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537257Phase 3Guangdong Second Provincial General HospitalVEN+IDAC vs IDAC in AML | 2027-04-01 |
| NCT06158269Institute of Hematology & Blood Diseases Hospital, ChinaDVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | 2026-12 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
| NCT06449846Zhujiang HospitalCompare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | 2026-12-31 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 78 studies in Neoplasm, Residual with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy. Minimal residual disease (MRD), an index for early treatment response, plays an important role in prognostic prediction. Numbers of data have shown MRD at day 14 after induction therapy significantly predicts prognosis. However, the retrospetive data from the investigators showed that patients with G-CSF treatment after induction had higher MRD at day 14 but not significantly different at day 28, suggesting that G-CSF might work on the differenciation of hemapoetic stem cells and increase MRD levels at day 14. In this multicenter prospective randomized controlled study, the effect of G-CSF on MRD after induction therapy in newly diagnosed acute myeloid leukemia (AML) is evaluated.
Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy. Minimal residual disease (MRD), an good index for early treatment response, plays an important role in prognostic prediction. Numbers of data have shown MRD at day 14 after induction therapy significantly predicts prognosis. However, the retrospetive data from the investigators showed that patients with G-CSF treatment after induction had higher MRD at day 14 but not significantly different at day 28,suggesting that G-CSF might work on the differenciation of hemapoetic stem cells and increase MRD level at day 14. In this multicenter prospective study, the investigators randomizedly divide all participants with newly diagnosed acute myeloid leukemia (AML) into G-CSF treatment group and G-SCF-free group. In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available in both G-CSF treatment and G-CSF-free groups. Comparision of the difference of MRD levels between the two groups is performed to evaluate the effect of G-CSF on MRD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Newly diagnosed AML exclusively of APL; 14-65 years old; Neutrophil \< 1.5 G/L at the day three after induction.
Exclusion Criteria:
Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure); Patients with any conditions not suitable for the trial; NR at day 28 after induction.
In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
Drug: G-SCF
In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
MRD1
MRD level is detested by flow cytometry at the day 14 after induction therapy.
Time frame: Day 14 after induction
OS rate
OS is the abbreviation of overall survival. OS rate is caculated as the ratio of survival participants versus total participants during the 2-year follow-up after diagosis.
Time frame: 2 years
DFS rate
DFS is the abbreviation of disease-free survival. DFS rate is caculated as the ratio of participants with continuous complete remission (CR) versus total participants abtaining CR after induction during the 2-year follow-up after diagosis.
Time frame: 2 years
Time for neutropenia
The lasting time for the patients with neutropenia after induction therapy
Time frame: 30 days after induction
Infection incidence
The incidence of infection after induction
Time frame: 30 days after induction
MRD2
MRD level is detested by flow cytometry at the day 28 after induction therapy.
Time frame: Day 28 after induction
Ran from Sep 2018 to primary completion in May 2022, 44 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2020 → May 2022 and completion Aug 2021 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University →